- Mylan Labs is partnering with Gilead to manufacture and distribute tenofovir alafenamide (TAF)-based HIV treatments to patients in the developing world.
- Gilead will transfer its technology to Mylan, and Mylan will make lost-cost versions of TAF-based treatments.
- Gilead's TAF is an investigational antiretroviral (ARV) drug that is being reviewed by the FDA.
Gilead has a history of trying to bring its high-tech drugs to low-income countries at affordable prices. For instance, the company struck a deal with seven Indian generics manufacturers over the fall to produce low-cost versions of hep C blockbusters Sovaldi and Harvoni that will be made available in more than 90 poor countries.
In this case, the population of HIV-infected people who stand to benefit from the Mylan partnership exceeds 30 million people—approximately 84% of all HIV-infected people in the world. That's certainly one way to honor World AIDS Day.